These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
577 related articles for article (PubMed ID: 35163013)
1. Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease. Hatton SL; Pandey MK Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163013 [TBL] [Abstract][Full Text] [Related]
2. Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. Allen Reish HE; Standaert DG J Parkinsons Dis; 2015; 5(1):1-19. PubMed ID: 25588354 [TBL] [Abstract][Full Text] [Related]
3. Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease. Mori A; Imai Y; Hattori N Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392751 [TBL] [Abstract][Full Text] [Related]
4. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease. Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665 [TBL] [Abstract][Full Text] [Related]
6. Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy. Delgado-Minjares KM; Martinez-Fong D; Martínez-Dávila IA; Bañuelos C; Gutierrez-Castillo ME; Blanco-Alvarez VM; Cardenas-Aguayo MD; Luna-Muñoz J; Pacheco-Herrero M; Soto-Rojas LO Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769132 [TBL] [Abstract][Full Text] [Related]
7. Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson's Disease. Cardinale A; Calabrese V; de Iure A; Picconi B Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204581 [TBL] [Abstract][Full Text] [Related]
8. The role of Toll-like receptors and neuroinflammation in Parkinson's disease. Heidari A; Yazdanpanah N; Rezaei N J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422 [TBL] [Abstract][Full Text] [Related]
9. Innate and adaptive immune responses in Parkinson's disease. Schonhoff AM; Williams GP; Wallen ZD; Standaert DG; Harms AS Prog Brain Res; 2020; 252():169-216. PubMed ID: 32247364 [TBL] [Abstract][Full Text] [Related]
10. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Sharma N; Rao SP; Kalivendi SV Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974 [TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015 [TBL] [Abstract][Full Text] [Related]
12. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Gustot A; Gallea JI; Sarroukh R; Celej MS; Ruysschaert JM; Raussens V Biochem J; 2015 Nov; 471(3):323-33. PubMed ID: 26272943 [TBL] [Abstract][Full Text] [Related]
13. Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson's Disease. Alecu I; Bennett SAL Front Neurosci; 2019; 13():328. PubMed ID: 31031582 [TBL] [Abstract][Full Text] [Related]
14. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608 [TBL] [Abstract][Full Text] [Related]
15. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease. Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147 [TBL] [Abstract][Full Text] [Related]
16. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Mehra S; Sahay S; Maji SK Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581 [TBL] [Abstract][Full Text] [Related]
17. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. Gelders G; Baekelandt V; Van der Perren A J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease. Kasen A; Houck C; Burmeister AR; Sha Q; Brundin L; Brundin P Neurobiol Dis; 2022 May; 166():105654. PubMed ID: 35143968 [TBL] [Abstract][Full Text] [Related]
19. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Harms AS; Ferreira SA; Romero-Ramos M Acta Neuropathol; 2021 Apr; 141(4):527-545. PubMed ID: 33555429 [TBL] [Abstract][Full Text] [Related]
20. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]